BNT162b2 mRNA疫苗接种六个月后抗SARS-CoV-2免疫反应概述

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.

作者信息

Gandolfo Claudia, Anichini Gabriele, Mugnaini Marco, Bocchia Monica, Terrosi Chiara, Sicuranza Anna, Gori Savellini Gianni, Gozzetti Alessandro, Franchi Federico, Cusi Maria Grazia

机构信息

Virology Unit, Department of Medical Biotechnologies, University of Siena, Azienda, Ospedaliera Universitaria Senese, V. le Bracci, 16, 53100 Siena, Italy.

Department of Information Engineering and Mathematical Sciences, University of Siena, 53100 Siena, Italy.

出版信息

Vaccines (Basel). 2022 Jan 22;10(2):171. doi: 10.3390/vaccines10020171.

BACKGROUND

We have designed a prospective study aiming to monitor the immune response in 178 health care workers six months after BNT162b2 mRNA vaccination.

METHODS

The humoral immune response of all subjects was evaluated by chemiluminescence (CMIA); in 60 serum samples, a live virus-based neutralization assay was also tested. Moreover, 6 months after vaccination, B- and T-cell subsets from 20 subjects were observed by FACS analysis after restimulation with the trimeric SARS-CoV-2 Spike protein as an antigen, thus mimicking reinfection in vitro.

RESULTS

A significant decrease of circulating IgG levels and neutralizing antibodies over time were observed. Moreover, six months after vaccination, a variable T-cell immune response after in vitro antigen stimulation of PBMC was observed. On the contrary, the analysis of B-cell response showed a shift from unswitched to switched memory B-cells and an increase of Th17 cells.

CONCLUSIONS

Although the variability of the CD4 and CD8 immune response and an antibody decline was observed among vaccinated subjects, the increase of switched memory B-cells and Th17 cells, correlating with the presence of neutralizing antibodies, opened the debate on the correct timing of vaccination.